Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1324 participants.
Also called NCT07944261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,324 participants
- Sponsor
- Registry
-
NCT07944261
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07944261. Randomized; single masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2029-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits
- Acronym
- MILD-EFFECT
- Condition
- Acute Ischemic Stroke
- Condition
- Minor Ischemic Stroke
- Intervention (Drug)
- Tenecteplase 0.18 mg/kg
- Intervention (Drug)
- Tenecteplase 0.25 mg/kg
- Lead sponsor
- Shandong Provincial Hospital
Record details
- Record id
cardio:ct-nct07944261- Content hash
a07a0ac47b4722f52a5bb80de48f1ea78c95c70c2aa4cf4709192772eaa17a51